nodes	percent_of_prediction	percent_of_DWPC	metapath
Propranolol—CYP3A7—Simvastatin—atherosclerosis	0.0513	0.0702	CbGbCtD
Propranolol—CYP3A7-CYP3A51P—Simvastatin—atherosclerosis	0.0513	0.0702	CbGbCtD
Propranolol—CYP3A7—Lovastatin—atherosclerosis	0.0502	0.0687	CbGbCtD
Propranolol—CYP3A7-CYP3A51P—Lovastatin—atherosclerosis	0.0502	0.0687	CbGbCtD
Propranolol—CYP3A5—Rosuvastatin—atherosclerosis	0.0414	0.0567	CbGbCtD
Propranolol—CYP3A5—Simvastatin—atherosclerosis	0.0385	0.0527	CbGbCtD
Propranolol—CYP3A5—Lovastatin—atherosclerosis	0.0376	0.0516	CbGbCtD
Propranolol—CYP3A5—Pravastatin—atherosclerosis	0.0376	0.0516	CbGbCtD
Propranolol—CYP2C19—Rosuvastatin—atherosclerosis	0.0334	0.0457	CbGbCtD
Propranolol—CYP2C19—Simvastatin—atherosclerosis	0.031	0.0425	CbGbCtD
Propranolol—CYP2C19—Lovastatin—atherosclerosis	0.0304	0.0416	CbGbCtD
Propranolol—CYP2D6—Niacin—atherosclerosis	0.0298	0.0409	CbGbCtD
Propranolol—ABCB1—Ezetimibe—atherosclerosis	0.0269	0.0369	CbGbCtD
Propranolol—ABCB1—Simvastatin—atherosclerosis	0.025	0.0343	CbGbCtD
Propranolol—ABCB1—Pravastatin—atherosclerosis	0.0245	0.0336	CbGbCtD
Propranolol—ABCB1—Lovastatin—atherosclerosis	0.0245	0.0336	CbGbCtD
Propranolol—CYP2D6—Simvastatin—atherosclerosis	0.0236	0.0323	CbGbCtD
Propranolol—CYP2D6—Lovastatin—atherosclerosis	0.0231	0.0316	CbGbCtD
Propranolol—CYP2D6—Pravastatin—atherosclerosis	0.0231	0.0316	CbGbCtD
Propranolol—CYP3A4—Rosuvastatin—atherosclerosis	0.0161	0.0221	CbGbCtD
Propranolol—CYP3A4—Ezetimibe—atherosclerosis	0.0161	0.0221	CbGbCtD
Propranolol—CYP3A4—Simvastatin—atherosclerosis	0.015	0.0205	CbGbCtD
Propranolol—CYP3A4—Lovastatin—atherosclerosis	0.0147	0.0201	CbGbCtD
Propranolol—CYP3A4—Pravastatin—atherosclerosis	0.0147	0.0201	CbGbCtD
Propranolol—Arterial thrombosis—Niacin—atherosclerosis	0.00534	0.0319	CcSEcCtD
Propranolol—Ache—Lovastatin—atherosclerosis	0.00363	0.0217	CcSEcCtD
Propranolol—Ache—Simvastatin—atherosclerosis	0.00339	0.0203	CcSEcCtD
Propranolol—Cinacalcet—CASR—atherosclerosis	0.00336	0.531	CrCbGaD
Propranolol—Ache—Pravastatin—atherosclerosis	0.00307	0.0183	CcSEcCtD
Propranolol—Systemic lupus erythematosus—Lovastatin—atherosclerosis	0.00302	0.0181	CcSEcCtD
Propranolol—Systemic lupus erythematosus—Simvastatin—atherosclerosis	0.00283	0.0169	CcSEcCtD
Propranolol—Myopathy—Rosuvastatin—atherosclerosis	0.00282	0.0168	CcSEcCtD
Propranolol—Systemic lupus erythematosus—Pravastatin—atherosclerosis	0.00256	0.0153	CcSEcCtD
Propranolol—Myopathy—Lovastatin—atherosclerosis	0.00239	0.0143	CcSEcCtD
Propranolol—Myopathy—Ezetimibe—atherosclerosis	0.00234	0.014	CcSEcCtD
Propranolol—Respiratory tract infection—Pravastatin—atherosclerosis	0.00225	0.0135	CcSEcCtD
Propranolol—Myopathy—Simvastatin—atherosclerosis	0.00223	0.0134	CcSEcCtD
Propranolol—Myopathy—Niacin—atherosclerosis	0.00205	0.0123	CcSEcCtD
Propranolol—Myopathy—Pravastatin—atherosclerosis	0.00202	0.0121	CcSEcCtD
Propranolol—Laryngospasm—Niacin—atherosclerosis	0.00193	0.0115	CcSEcCtD
Propranolol—Nightmare—Rosuvastatin—atherosclerosis	0.00191	0.0114	CcSEcCtD
Propranolol—Skin ulcer—Niacin—atherosclerosis	0.00185	0.011	CcSEcCtD
Propranolol—Sleep disorder—Rosuvastatin—atherosclerosis	0.00166	0.00991	CcSEcCtD
Propranolol—Amnesia—Rosuvastatin—atherosclerosis	0.00153	0.00913	CcSEcCtD
Propranolol—Nightmare—Simvastatin—atherosclerosis	0.00151	0.00904	CcSEcCtD
Propranolol—Nightmare—Pravastatin—atherosclerosis	0.00137	0.00818	CcSEcCtD
Propranolol—Vascular purpura—Lovastatin—atherosclerosis	0.00136	0.00813	CcSEcCtD
Propranolol—Sleep disorder—Simvastatin—atherosclerosis	0.00131	0.00785	CcSEcCtD
Propranolol—Carvedilol—SELE—atherosclerosis	0.00131	0.206	CrCbGaD
Propranolol—Amnesia—Lovastatin—atherosclerosis	0.00129	0.00774	CcSEcCtD
Propranolol—Vascular purpura—Simvastatin—atherosclerosis	0.00127	0.0076	CcSEcCtD
Propranolol—Amnesia—Ezetimibe—atherosclerosis	0.00127	0.00759	CcSEcCtD
Propranolol—Purpura—Lovastatin—atherosclerosis	0.00126	0.00754	CcSEcCtD
Propranolol—Carvedilol—VCAM1—atherosclerosis	0.00124	0.197	CrCbGaD
Propranolol—Amnesia—Simvastatin—atherosclerosis	0.00121	0.00724	CcSEcCtD
Propranolol—Bronchitis—Rosuvastatin—atherosclerosis	0.00119	0.00713	CcSEcCtD
Propranolol—Sleep disorder—Pravastatin—atherosclerosis	0.00119	0.0071	CcSEcCtD
Propranolol—Purpura—Simvastatin—atherosclerosis	0.00118	0.00705	CcSEcCtD
Propranolol—Vascular purpura—Pravastatin—atherosclerosis	0.00115	0.00687	CcSEcCtD
Propranolol—Depression—Rosuvastatin—atherosclerosis	0.0011	0.00659	CcSEcCtD
Propranolol—Toxic epidermal necrolysis—Lovastatin—atherosclerosis	0.00109	0.00655	CcSEcCtD
Propranolol—Amnesia—Pravastatin—atherosclerosis	0.00109	0.00654	CcSEcCtD
Propranolol—Purpura—Pravastatin—atherosclerosis	0.00107	0.00638	CcSEcCtD
Propranolol—Toxic epidermal necrolysis—Simvastatin—atherosclerosis	0.00102	0.00612	CcSEcCtD
Propranolol—Affect lability—Pravastatin—atherosclerosis	0.00101	0.00605	CcSEcCtD
Propranolol—Pharyngitis—Rosuvastatin—atherosclerosis	0.000985	0.00589	CcSEcCtD
Propranolol—Mood swings—Pravastatin—atherosclerosis	0.000974	0.00582	CcSEcCtD
Propranolol—Erectile dysfunction—Lovastatin—atherosclerosis	0.000968	0.00579	CcSEcCtD
Propranolol—Erectile dysfunction—Ezetimibe—atherosclerosis	0.000949	0.00567	CcSEcCtD
Propranolol—Bronchitis—Simvastatin—atherosclerosis	0.000945	0.00565	CcSEcCtD
Propranolol—Stevens-Johnson syndrome—Lovastatin—atherosclerosis	0.000929	0.00555	CcSEcCtD
Propranolol—Toxic epidermal necrolysis—Pravastatin—atherosclerosis	0.000926	0.00553	CcSEcCtD
Propranolol—Infestation—Ezetimibe—atherosclerosis	0.000919	0.00549	CcSEcCtD
Propranolol—Infestation NOS—Ezetimibe—atherosclerosis	0.000919	0.00549	CcSEcCtD
Propranolol—Erectile dysfunction—Simvastatin—atherosclerosis	0.000905	0.00541	CcSEcCtD
Propranolol—Depression—Simvastatin—atherosclerosis	0.000874	0.00522	CcSEcCtD
Propranolol—Mental disorder—Rosuvastatin—atherosclerosis	0.000869	0.0052	CcSEcCtD
Propranolol—Stevens-Johnson syndrome—Simvastatin—atherosclerosis	0.000869	0.00519	CcSEcCtD
Propranolol—Bronchitis—Niacin—atherosclerosis	0.000868	0.00519	CcSEcCtD
Propranolol—Erectile dysfunction—Niacin—atherosclerosis	0.000831	0.00497	CcSEcCtD
Propranolol—Pharyngitis—Ezetimibe—atherosclerosis	0.000819	0.00489	CcSEcCtD
Propranolol—Erectile dysfunction—Pravastatin—atherosclerosis	0.000818	0.00489	CcSEcCtD
Propranolol—Erythema multiforme—Lovastatin—atherosclerosis	0.000795	0.00475	CcSEcCtD
Propranolol—Depression—Pravastatin—atherosclerosis	0.00079	0.00472	CcSEcCtD
Propranolol—Stevens-Johnson syndrome—Pravastatin—atherosclerosis	0.000785	0.0047	CcSEcCtD
Propranolol—Erythema multiforme—Ezetimibe—atherosclerosis	0.00078	0.00466	CcSEcCtD
Propranolol—Cough—Rosuvastatin—atherosclerosis	0.000754	0.00451	CcSEcCtD
Propranolol—Erythema multiforme—Simvastatin—atherosclerosis	0.000744	0.00445	CcSEcCtD
Propranolol—Alopecia—Lovastatin—atherosclerosis	0.000743	0.00444	CcSEcCtD
Propranolol—Alopecia—Ezetimibe—atherosclerosis	0.000729	0.00436	CcSEcCtD
Propranolol—Mental disorder—Ezetimibe—atherosclerosis	0.000723	0.00432	CcSEcCtD
Propranolol—Erythema—Ezetimibe—atherosclerosis	0.000718	0.00429	CcSEcCtD
Propranolol—Pharyngitis—Pravastatin—atherosclerosis	0.000706	0.00422	CcSEcCtD
Propranolol—Infection—Rosuvastatin—atherosclerosis	0.0007	0.00419	CcSEcCtD
Propranolol—Visual impairment—Niacin—atherosclerosis	0.000696	0.00416	CcSEcCtD
Propranolol—Alopecia—Simvastatin—atherosclerosis	0.000695	0.00416	CcSEcCtD
Propranolol—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000691	0.00413	CcSEcCtD
Propranolol—Mental disorder—Simvastatin—atherosclerosis	0.000689	0.00412	CcSEcCtD
Propranolol—Visual impairment—Pravastatin—atherosclerosis	0.000685	0.0041	CcSEcCtD
Propranolol—Erythema—Simvastatin—atherosclerosis	0.000685	0.00409	CcSEcCtD
Propranolol—Erythema multiforme—Pravastatin—atherosclerosis	0.000672	0.00402	CcSEcCtD
Propranolol—Cardiac disorder—Pravastatin—atherosclerosis	0.00066	0.00395	CcSEcCtD
Propranolol—Vertigo—Lovastatin—atherosclerosis	0.000658	0.00393	CcSEcCtD
Propranolol—Alopecia—Niacin—atherosclerosis	0.000638	0.00382	CcSEcCtD
Propranolol—Insomnia—Rosuvastatin—atherosclerosis	0.000638	0.00381	CcSEcCtD
Propranolol—Paraesthesia—Rosuvastatin—atherosclerosis	0.000633	0.00379	CcSEcCtD
Propranolol—Erythema—Niacin—atherosclerosis	0.000629	0.00376	CcSEcCtD
Propranolol—Alopecia—Pravastatin—atherosclerosis	0.000628	0.00376	CcSEcCtD
Propranolol—Cough—Ezetimibe—atherosclerosis	0.000626	0.00375	CcSEcCtD
Propranolol—Dyspepsia—Rosuvastatin—atherosclerosis	0.000621	0.00371	CcSEcCtD
Propranolol—Vertigo—Simvastatin—atherosclerosis	0.000615	0.00368	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000607	0.00363	CcSEcCtD
Propranolol—Constipation—Rosuvastatin—atherosclerosis	0.000603	0.0036	CcSEcCtD
Propranolol—Pain—Rosuvastatin—atherosclerosis	0.000603	0.0036	CcSEcCtD
Propranolol—Anaphylactic shock—Lovastatin—atherosclerosis	0.000597	0.00357	CcSEcCtD
Propranolol—Infection—Lovastatin—atherosclerosis	0.000593	0.00355	CcSEcCtD
Propranolol—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000586	0.0035	CcSEcCtD
Propranolol—Infection—Ezetimibe—atherosclerosis	0.000582	0.00348	CcSEcCtD
Propranolol—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000576	0.00345	CcSEcCtD
Propranolol—Nervous system disorder—Ezetimibe—atherosclerosis	0.000575	0.00344	CcSEcCtD
Propranolol—Skin disorder—Ezetimibe—atherosclerosis	0.000569	0.0034	CcSEcCtD
Propranolol—Vertigo—Niacin—atherosclerosis	0.000565	0.00338	CcSEcCtD
Propranolol—Urticaria—Rosuvastatin—atherosclerosis	0.00056	0.00335	CcSEcCtD
Propranolol—Anaphylactic shock—Simvastatin—atherosclerosis	0.000559	0.00334	CcSEcCtD
Propranolol—Abdominal pain—Rosuvastatin—atherosclerosis	0.000557	0.00333	CcSEcCtD
Propranolol—Vertigo—Pravastatin—atherosclerosis	0.000556	0.00333	CcSEcCtD
Propranolol—Infection—Simvastatin—atherosclerosis	0.000555	0.00332	CcSEcCtD
Propranolol—Cough—Niacin—atherosclerosis	0.000549	0.00328	CcSEcCtD
Propranolol—Insomnia—Lovastatin—atherosclerosis	0.00054	0.00323	CcSEcCtD
Propranolol—Cough—Pravastatin—atherosclerosis	0.00054	0.00323	CcSEcCtD
Propranolol—Paraesthesia—Lovastatin—atherosclerosis	0.000536	0.00321	CcSEcCtD
Propranolol—Dyspnoea—Lovastatin—atherosclerosis	0.000533	0.00318	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000532	0.00318	CcSEcCtD
Propranolol—Insomnia—Ezetimibe—atherosclerosis	0.00053	0.00317	CcSEcCtD
Propranolol—Paraesthesia—Ezetimibe—atherosclerosis	0.000526	0.00315	CcSEcCtD
Propranolol—Dyspepsia—Lovastatin—atherosclerosis	0.000526	0.00314	CcSEcCtD
Propranolol—Dyspnoea—Ezetimibe—atherosclerosis	0.000522	0.00312	CcSEcCtD
Propranolol—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000519	0.00311	CcSEcCtD
Propranolol—Decreased appetite—Lovastatin—atherosclerosis	0.000519	0.00311	CcSEcCtD
Propranolol—Dyspepsia—Ezetimibe—atherosclerosis	0.000516	0.00308	CcSEcCtD
Propranolol—Fatigue—Lovastatin—atherosclerosis	0.000515	0.00308	CcSEcCtD
Propranolol—Anaphylactic shock—Niacin—atherosclerosis	0.000513	0.00307	CcSEcCtD
Propranolol—Constipation—Lovastatin—atherosclerosis	0.000511	0.00305	CcSEcCtD
Propranolol—Pain—Lovastatin—atherosclerosis	0.000511	0.00305	CcSEcCtD
Propranolol—Decreased appetite—Ezetimibe—atherosclerosis	0.000509	0.00305	CcSEcCtD
Propranolol—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000506	0.00303	CcSEcCtD
Propranolol—Asthenia—Rosuvastatin—atherosclerosis	0.000506	0.00302	CcSEcCtD
Propranolol—Insomnia—Simvastatin—atherosclerosis	0.000505	0.00302	CcSEcCtD
Propranolol—Anaphylactic shock—Pravastatin—atherosclerosis	0.000505	0.00302	CcSEcCtD
Propranolol—Fatigue—Ezetimibe—atherosclerosis	0.000505	0.00302	CcSEcCtD
Propranolol—Infection—Pravastatin—atherosclerosis	0.000502	0.003	CcSEcCtD
Propranolol—Paraesthesia—Simvastatin—atherosclerosis	0.000502	0.003	CcSEcCtD
Propranolol—Pain—Ezetimibe—atherosclerosis	0.000501	0.003	CcSEcCtD
Propranolol—Constipation—Ezetimibe—atherosclerosis	0.000501	0.003	CcSEcCtD
Propranolol—Skin disorder—Niacin—atherosclerosis	0.000498	0.00298	CcSEcCtD
Propranolol—Dyspnoea—Simvastatin—atherosclerosis	0.000498	0.00298	CcSEcCtD
Propranolol—Dyspepsia—Simvastatin—atherosclerosis	0.000492	0.00294	CcSEcCtD
Propranolol—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000489	0.00292	CcSEcCtD
Propranolol—Decreased appetite—Simvastatin—atherosclerosis	0.000486	0.0029	CcSEcCtD
Propranolol—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000482	0.00288	CcSEcCtD
Propranolol—Diarrhoea—Rosuvastatin—atherosclerosis	0.000482	0.00288	CcSEcCtD
Propranolol—Fatigue—Simvastatin—atherosclerosis	0.000482	0.00288	CcSEcCtD
Propranolol—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000479	0.00287	CcSEcCtD
Propranolol—Pain—Simvastatin—atherosclerosis	0.000478	0.00286	CcSEcCtD
Propranolol—Constipation—Simvastatin—atherosclerosis	0.000478	0.00286	CcSEcCtD
Propranolol—Urticaria—Lovastatin—atherosclerosis	0.000475	0.00284	CcSEcCtD
Propranolol—Abdominal pain—Lovastatin—atherosclerosis	0.000472	0.00282	CcSEcCtD
Propranolol—Body temperature increased—Lovastatin—atherosclerosis	0.000472	0.00282	CcSEcCtD
Propranolol—Dizziness—Rosuvastatin—atherosclerosis	0.000466	0.00279	CcSEcCtD
Propranolol—Urticaria—Ezetimibe—atherosclerosis	0.000465	0.00278	CcSEcCtD
Propranolol—Insomnia—Niacin—atherosclerosis	0.000464	0.00278	CcSEcCtD
Propranolol—Abdominal pain—Ezetimibe—atherosclerosis	0.000463	0.00277	CcSEcCtD
Propranolol—Body temperature increased—Ezetimibe—atherosclerosis	0.000463	0.00277	CcSEcCtD
Propranolol—Paraesthesia—Niacin—atherosclerosis	0.000461	0.00276	CcSEcCtD
Propranolol—Dyspnoea—Niacin—atherosclerosis	0.000457	0.00274	CcSEcCtD
Propranolol—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000457	0.00273	CcSEcCtD
Propranolol—Insomnia—Pravastatin—atherosclerosis	0.000457	0.00273	CcSEcCtD
Propranolol—Somnolence—Niacin—atherosclerosis	0.000456	0.00273	CcSEcCtD
Propranolol—Paraesthesia—Pravastatin—atherosclerosis	0.000454	0.00271	CcSEcCtD
Propranolol—Dyspepsia—Niacin—atherosclerosis	0.000452	0.0027	CcSEcCtD
Propranolol—Dyspnoea—Pravastatin—atherosclerosis	0.00045	0.00269	CcSEcCtD
Propranolol—Decreased appetite—Niacin—atherosclerosis	0.000446	0.00267	CcSEcCtD
Propranolol—Dyspepsia—Pravastatin—atherosclerosis	0.000445	0.00266	CcSEcCtD
Propranolol—Rash—Rosuvastatin—atherosclerosis	0.000444	0.00266	CcSEcCtD
Propranolol—Dermatitis—Rosuvastatin—atherosclerosis	0.000444	0.00266	CcSEcCtD
Propranolol—Urticaria—Simvastatin—atherosclerosis	0.000444	0.00265	CcSEcCtD
Propranolol—Gastrointestinal disorder—Niacin—atherosclerosis	0.000443	0.00265	CcSEcCtD
Propranolol—Body temperature increased—Simvastatin—atherosclerosis	0.000442	0.00264	CcSEcCtD
Propranolol—Abdominal pain—Simvastatin—atherosclerosis	0.000442	0.00264	CcSEcCtD
Propranolol—Hypersensitivity—Lovastatin—atherosclerosis	0.00044	0.00263	CcSEcCtD
Propranolol—Decreased appetite—Pravastatin—atherosclerosis	0.000439	0.00263	CcSEcCtD
Propranolol—Pain—Niacin—atherosclerosis	0.000439	0.00262	CcSEcCtD
Propranolol—Fatigue—Pravastatin—atherosclerosis	0.000436	0.0026	CcSEcCtD
Propranolol—Pain—Pravastatin—atherosclerosis	0.000432	0.00258	CcSEcCtD
Propranolol—Constipation—Pravastatin—atherosclerosis	0.000432	0.00258	CcSEcCtD
Propranolol—Hypersensitivity—Ezetimibe—atherosclerosis	0.000432	0.00258	CcSEcCtD
Propranolol—Asthenia—Lovastatin—atherosclerosis	0.000429	0.00256	CcSEcCtD
Propranolol—Asthenia—Ezetimibe—atherosclerosis	0.00042	0.00251	CcSEcCtD
Propranolol—Carvedilol—VEGFA—atherosclerosis	0.00042	0.0664	CrCbGaD
Propranolol—Gastrointestinal pain—Niacin—atherosclerosis	0.00042	0.00251	CcSEcCtD
Propranolol—Nausea—Rosuvastatin—atherosclerosis	0.000419	0.0025	CcSEcCtD
Propranolol—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000413	0.00247	CcSEcCtD
Propranolol—Hypersensitivity—Simvastatin—atherosclerosis	0.000412	0.00246	CcSEcCtD
Propranolol—Diarrhoea—Lovastatin—atherosclerosis	0.000409	0.00244	CcSEcCtD
Propranolol—Urticaria—Niacin—atherosclerosis	0.000408	0.00244	CcSEcCtD
Propranolol—Abdominal pain—Niacin—atherosclerosis	0.000406	0.00243	CcSEcCtD
Propranolol—Body temperature increased—Niacin—atherosclerosis	0.000406	0.00243	CcSEcCtD
Propranolol—Urticaria—Pravastatin—atherosclerosis	0.000401	0.0024	CcSEcCtD
Propranolol—Asthenia—Simvastatin—atherosclerosis	0.000401	0.0024	CcSEcCtD
Propranolol—Diarrhoea—Ezetimibe—atherosclerosis	0.000401	0.0024	CcSEcCtD
Propranolol—Abdominal pain—Pravastatin—atherosclerosis	0.000399	0.00239	CcSEcCtD
Propranolol—Body temperature increased—Pravastatin—atherosclerosis	0.000399	0.00239	CcSEcCtD
Propranolol—Dizziness—Lovastatin—atherosclerosis	0.000395	0.00236	CcSEcCtD
Propranolol—Dizziness—Ezetimibe—atherosclerosis	0.000387	0.00232	CcSEcCtD
Propranolol—Diarrhoea—Simvastatin—atherosclerosis	0.000382	0.00229	CcSEcCtD
Propranolol—Vomiting—Lovastatin—atherosclerosis	0.00038	0.00227	CcSEcCtD
Propranolol—Hypersensitivity—Niacin—atherosclerosis	0.000378	0.00226	CcSEcCtD
Propranolol—Rash—Lovastatin—atherosclerosis	0.000377	0.00225	CcSEcCtD
Propranolol—Dermatitis—Lovastatin—atherosclerosis	0.000376	0.00225	CcSEcCtD
Propranolol—Vomiting—Ezetimibe—atherosclerosis	0.000373	0.00223	CcSEcCtD
Propranolol—Hypersensitivity—Pravastatin—atherosclerosis	0.000372	0.00223	CcSEcCtD
Propranolol—Dizziness—Simvastatin—atherosclerosis	0.00037	0.00221	CcSEcCtD
Propranolol—Rash—Ezetimibe—atherosclerosis	0.000369	0.00221	CcSEcCtD
Propranolol—Dermatitis—Ezetimibe—atherosclerosis	0.000369	0.00221	CcSEcCtD
Propranolol—Asthenia—Niacin—atherosclerosis	0.000368	0.0022	CcSEcCtD
Propranolol—Asthenia—Pravastatin—atherosclerosis	0.000362	0.00217	CcSEcCtD
Propranolol—Vomiting—Simvastatin—atherosclerosis	0.000355	0.00212	CcSEcCtD
Propranolol—Nausea—Lovastatin—atherosclerosis	0.000355	0.00212	CcSEcCtD
Propranolol—Rash—Simvastatin—atherosclerosis	0.000352	0.00211	CcSEcCtD
Propranolol—Dermatitis—Simvastatin—atherosclerosis	0.000352	0.0021	CcSEcCtD
Propranolol—Diarrhoea—Niacin—atherosclerosis	0.000351	0.0021	CcSEcCtD
Propranolol—Nausea—Ezetimibe—atherosclerosis	0.000348	0.00208	CcSEcCtD
Propranolol—Diarrhoea—Pravastatin—atherosclerosis	0.000346	0.00207	CcSEcCtD
Propranolol—Dizziness—Niacin—atherosclerosis	0.000339	0.00203	CcSEcCtD
Propranolol—Dizziness—Pravastatin—atherosclerosis	0.000334	0.002	CcSEcCtD
Propranolol—Nausea—Simvastatin—atherosclerosis	0.000332	0.00198	CcSEcCtD
Propranolol—Vomiting—Niacin—atherosclerosis	0.000326	0.00195	CcSEcCtD
Propranolol—Rash—Niacin—atherosclerosis	0.000324	0.00193	CcSEcCtD
Propranolol—Dermatitis—Niacin—atherosclerosis	0.000323	0.00193	CcSEcCtD
Propranolol—Vomiting—Pravastatin—atherosclerosis	0.000321	0.00192	CcSEcCtD
Propranolol—Rash—Pravastatin—atherosclerosis	0.000319	0.0019	CcSEcCtD
Propranolol—Dermatitis—Pravastatin—atherosclerosis	0.000318	0.0019	CcSEcCtD
Propranolol—Nausea—Niacin—atherosclerosis	0.000305	0.00182	CcSEcCtD
Propranolol—Nausea—Pravastatin—atherosclerosis	0.0003	0.00179	CcSEcCtD
Propranolol—CYP2C19—Metabolism—ABCA1—atherosclerosis	9e-06	9.32e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—APOA1—atherosclerosis	8.99e-06	9.31e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—APOC3—atherosclerosis	8.97e-06	9.28e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—GPX1—atherosclerosis	8.92e-06	9.23e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—LDLR—atherosclerosis	8.91e-06	9.23e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—APOE—atherosclerosis	8.89e-06	9.21e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—LEP—atherosclerosis	8.89e-06	9.21e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—ESR1—atherosclerosis	8.88e-06	9.19e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CAV1—atherosclerosis	8.81e-06	9.12e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—GSTM1—atherosclerosis	8.8e-06	9.11e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—APOA1—atherosclerosis	8.79e-06	9.1e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—ABCA1—atherosclerosis	8.79e-06	9.1e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—F2—atherosclerosis	8.77e-06	9.08e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—LPA—atherosclerosis	8.76e-06	9.08e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—NOS3—atherosclerosis	8.75e-06	9.06e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—CETP—atherosclerosis	8.7e-06	9.01e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—ESR1—atherosclerosis	8.68e-06	8.99e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—CD36—atherosclerosis	8.68e-06	8.99e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—LPL—atherosclerosis	8.63e-06	8.94e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—F2—atherosclerosis	8.58e-06	8.88e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—ESR1—atherosclerosis	8.49e-06	8.79e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—BGN—atherosclerosis	8.49e-06	8.79e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—VEGFA—atherosclerosis	8.45e-06	8.76e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—GPX1—atherosclerosis	8.42e-06	8.72e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—APOA5—atherosclerosis	8.4e-06	8.7e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—PIK3CG—atherosclerosis	8.39e-06	8.69e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—F2—atherosclerosis	8.39e-06	8.69e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—STAT3—atherosclerosis	8.37e-06	8.67e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—SCARB1—atherosclerosis	8.33e-06	8.63e-05	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—ALB—atherosclerosis	8.3e-06	8.6e-05	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—ALB—atherosclerosis	8.29e-06	8.58e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—ABCA1—atherosclerosis	8.28e-06	8.58e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—MTHFR—atherosclerosis	8.23e-06	8.52e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—PIK3CG—atherosclerosis	8.21e-06	8.5e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—CD36—atherosclerosis	8.2e-06	8.5e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	8.12e-06	8.4e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	8.09e-06	8.38e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PPARA—atherosclerosis	8.07e-06	8.36e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—MAPK3—atherosclerosis	8.04e-06	8.32e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—PIK3CG—atherosclerosis	8.03e-06	8.31e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—MAPK3—atherosclerosis	8e-06	8.28e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—INS—atherosclerosis	7.94e-06	8.23e-05	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—NOS3—atherosclerosis	7.94e-06	8.22e-05	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—NOS3—atherosclerosis	7.93e-06	8.21e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—HMGCR—atherosclerosis	7.87e-06	8.15e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—MAPK3—atherosclerosis	7.86e-06	8.14e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—AGT—atherosclerosis	7.82e-06	8.1e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CCL2—atherosclerosis	7.81e-06	8.09e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—ALOX5—atherosclerosis	7.81e-06	8.09e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—MTHFR—atherosclerosis	7.77e-06	8.05e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—INS—atherosclerosis	7.77e-06	8.05e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—TGFB1—atherosclerosis	7.76e-06	8.04e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CXCL8—atherosclerosis	7.76e-06	8.03e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—HMOX1—atherosclerosis	7.72e-06	8e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—MAPK3—atherosclerosis	7.69e-06	7.96e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—IGF1—atherosclerosis	7.68e-06	7.96e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—APOE—atherosclerosis	7.66e-06	7.93e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CCL2—atherosclerosis	7.64e-06	7.92e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PPARA—atherosclerosis	7.63e-06	7.9e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—INS—atherosclerosis	7.6e-06	7.87e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—CAV1—atherosclerosis	7.59e-06	7.86e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—APOA1—atherosclerosis	7.57e-06	7.84e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—HMOX1—atherosclerosis	7.54e-06	7.81e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—IGF1—atherosclerosis	7.52e-06	7.78e-05	CbGpPWpGaD
Propranolol—HTR1B—GPCR downstream signaling—AKT1—atherosclerosis	7.49e-06	7.76e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CCL2—atherosclerosis	7.48e-06	7.74e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—APOB—atherosclerosis	7.4e-06	7.66e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—AGT—atherosclerosis	7.39e-06	7.65e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—IL6—atherosclerosis	7.38e-06	7.64e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—IGF1—atherosclerosis	7.35e-06	7.61e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—SERPINE1—atherosclerosis	7.3e-06	7.56e-05	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—PTGS2—atherosclerosis	7.26e-06	7.52e-05	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—PTGS2—atherosclerosis	7.25e-06	7.51e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—APOE—atherosclerosis	7.24e-06	7.49e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—APOB—atherosclerosis	7.22e-06	7.48e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—GSTM1—atherosclerosis	7.2e-06	7.45e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—CAV1—atherosclerosis	7.17e-06	7.43e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—APOA1—atherosclerosis	7.15e-06	7.41e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—SERPINE1—atherosclerosis	7.14e-06	7.39e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—HMOX1—atherosclerosis	7.11e-06	7.36e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	7.1e-06	7.35e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—LPL—atherosclerosis	7.07e-06	7.32e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—GSTM1—atherosclerosis	7.03e-06	7.28e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—MMP9—atherosclerosis	7.02e-06	7.27e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—ABCA1—atherosclerosis	7.02e-06	7.27e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—NAMPT—atherosclerosis	7.01e-06	7.26e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—SERPINE1—atherosclerosis	6.98e-06	7.23e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—NOS3—atherosclerosis	6.97e-06	7.21e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—LIPC—atherosclerosis	6.96e-06	7.21e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—NFKB1—atherosclerosis	6.94e-06	7.19e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—APOC3—atherosclerosis	6.92e-06	7.17e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PIK3CG—atherosclerosis	6.91e-06	7.16e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—LPL—atherosclerosis	6.9e-06	7.14e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—GPX1—atherosclerosis	6.89e-06	7.14e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—LDLR—atherosclerosis	6.88e-06	7.12e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—MAPK8—atherosclerosis	6.82e-06	7.07e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—NOS3—atherosclerosis	6.81e-06	7.06e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—AKT1—atherosclerosis	6.81e-06	7.05e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—APOB—atherosclerosis	6.81e-06	7.05e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—GPX1—atherosclerosis	6.73e-06	6.97e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—CETP—atherosclerosis	6.72e-06	6.96e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—CD36—atherosclerosis	6.71e-06	6.95e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PPARG—atherosclerosis	6.67e-06	6.91e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—NOS3—atherosclerosis	6.66e-06	6.9e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—GSTM1—atherosclerosis	6.62e-06	6.86e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—CD36—atherosclerosis	6.55e-06	6.79e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—INS—atherosclerosis	6.54e-06	6.78e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PIK3CG—atherosclerosis	6.53e-06	6.76e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—LPL—atherosclerosis	6.5e-06	6.73e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—SCARB1—atherosclerosis	6.43e-06	6.66e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—MTHFR—atherosclerosis	6.36e-06	6.59e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—GPX1—atherosclerosis	6.34e-06	6.57e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PPARG—atherosclerosis	6.3e-06	6.53e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—VEGFA—atherosclerosis	6.3e-06	6.53e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PPARA—atherosclerosis	6.24e-06	6.46e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—STAT3—atherosclerosis	6.24e-06	6.46e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—MTHFR—atherosclerosis	6.21e-06	6.43e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—INS—atherosclerosis	6.18e-06	6.4e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CXCL8—atherosclerosis	6.18e-06	6.4e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—CD36—atherosclerosis	6.17e-06	6.39e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PPARA—atherosclerosis	6.09e-06	6.31e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—HMGCR—atherosclerosis	6.07e-06	6.29e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—AGT—atherosclerosis	6.04e-06	6.26e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CXCL8—atherosclerosis	6.04e-06	6.26e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—HMOX1—atherosclerosis	6.02e-06	6.23e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—ALB—atherosclerosis	6e-06	6.21e-05	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—AKT1—atherosclerosis	5.97e-06	6.18e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—MAPK3—atherosclerosis	5.96e-06	6.17e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—APOE—atherosclerosis	5.92e-06	6.13e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CXCL8—atherosclerosis	5.91e-06	6.12e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—AGT—atherosclerosis	5.9e-06	6.11e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—IL6—atherosclerosis	5.88e-06	6.08e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—CAV1—atherosclerosis	5.87e-06	6.08e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—APOA1—atherosclerosis	5.85e-06	6.06e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—MTHFR—atherosclerosis	5.85e-06	6.06e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—IL6—atherosclerosis	5.85e-06	6.06e-05	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—AKT1—atherosclerosis	5.84e-06	6.05e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—TGFB1—atherosclerosis	5.78e-06	5.99e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—APOE—atherosclerosis	5.78e-06	5.99e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—APOB—atherosclerosis	5.77e-06	5.97e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—IL6—atherosclerosis	5.75e-06	5.95e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PPARA—atherosclerosis	5.74e-06	5.94e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—NOS3—atherosclerosis	5.74e-06	5.94e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—CAV1—atherosclerosis	5.73e-06	5.93e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—APOA1—atherosclerosis	5.71e-06	5.92e-05	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—AKT1—atherosclerosis	5.71e-06	5.91e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—ALB—atherosclerosis	5.67e-06	5.87e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—IL6—atherosclerosis	5.62e-06	5.82e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—GSTM1—atherosclerosis	5.61e-06	5.81e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—MMP9—atherosclerosis	5.59e-06	5.79e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—AGT—atherosclerosis	5.56e-06	5.76e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—NFKB1—atherosclerosis	5.53e-06	5.73e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—LPL—atherosclerosis	5.51e-06	5.7e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—MMP9—atherosclerosis	5.47e-06	5.66e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—APOE—atherosclerosis	5.45e-06	5.64e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—MAPK8—atherosclerosis	5.44e-06	5.63e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—NOS3—atherosclerosis	5.42e-06	5.61e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—AKT1—atherosclerosis	5.42e-06	5.61e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—ABCA1—atherosclerosis	5.41e-06	5.61e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—NFKB1—atherosclerosis	5.41e-06	5.6e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—CAV1—atherosclerosis	5.4e-06	5.59e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—AKT1—atherosclerosis	5.39e-06	5.59e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—APOA1—atherosclerosis	5.38e-06	5.58e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—GPX1—atherosclerosis	5.37e-06	5.56e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—MMP9—atherosclerosis	5.35e-06	5.54e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PIK3CG—atherosclerosis	5.34e-06	5.53e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—MAPK8—atherosclerosis	5.32e-06	5.51e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—AKT1—atherosclerosis	5.3e-06	5.49e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—NFKB1—atherosclerosis	5.29e-06	5.48e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PTGS2—atherosclerosis	5.25e-06	5.44e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—CD36—atherosclerosis	5.23e-06	5.42e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PIK3CG—atherosclerosis	5.22e-06	5.4e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—MAPK8—atherosclerosis	5.2e-06	5.38e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—AKT1—atherosclerosis	5.18e-06	5.37e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PPARG—atherosclerosis	5.16e-06	5.34e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—INS—atherosclerosis	5.06e-06	5.24e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PPARG—atherosclerosis	5.03e-06	5.21e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—VEGFA—atherosclerosis	5.02e-06	5.2e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—STAT3—atherosclerosis	4.97e-06	5.15e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PTGS2—atherosclerosis	4.96e-06	5.14e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—MTHFR—atherosclerosis	4.96e-06	5.13e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—INS—atherosclerosis	4.94e-06	5.11e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PIK3CG—atherosclerosis	4.92e-06	5.09e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—VEGFA—atherosclerosis	4.91e-06	5.08e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PPARA—atherosclerosis	4.86e-06	5.04e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—STAT3—atherosclerosis	4.86e-06	5.03e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—VEGFA—atherosclerosis	4.8e-06	4.97e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—STAT3—atherosclerosis	4.75e-06	4.92e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—MAPK3—atherosclerosis	4.75e-06	4.92e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PPARG—atherosclerosis	4.74e-06	4.91e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—AGT—atherosclerosis	4.71e-06	4.88e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—INS—atherosclerosis	4.65e-06	4.82e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—HMOX1—atherosclerosis	4.65e-06	4.81e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—MAPK3—atherosclerosis	4.64e-06	4.81e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—ALB—atherosclerosis	4.64e-06	4.8e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—APOE—atherosclerosis	4.61e-06	4.78e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—TGFB1—atherosclerosis	4.61e-06	4.77e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—CAV1—atherosclerosis	4.57e-06	4.73e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—APOA1—atherosclerosis	4.56e-06	4.72e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—MAPK3—atherosclerosis	4.54e-06	4.7e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—ALB—atherosclerosis	4.53e-06	4.69e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—TGFB1—atherosclerosis	4.51e-06	4.67e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—APOB—atherosclerosis	4.45e-06	4.61e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—NOS3—atherosclerosis	4.44e-06	4.59e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—TGFB1—atherosclerosis	4.41e-06	4.56e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—IL6—atherosclerosis	4.36e-06	4.51e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—NOS3—atherosclerosis	4.33e-06	4.48e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—GSTM1—atherosclerosis	4.33e-06	4.48e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—ALB—atherosclerosis	4.27e-06	4.42e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—LPL—atherosclerosis	4.25e-06	4.4e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PIK3CG—atherosclerosis	4.16e-06	4.31e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—GPX1—atherosclerosis	4.15e-06	4.29e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—NOS3—atherosclerosis	4.08e-06	4.23e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PTGS2—atherosclerosis	4.06e-06	4.2e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—CD36—atherosclerosis	4.04e-06	4.18e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—AKT1—atherosclerosis	4.02e-06	4.16e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PPARG—atherosclerosis	4.02e-06	4.16e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PTGS2—atherosclerosis	3.96e-06	4.1e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—INS—atherosclerosis	3.94e-06	4.08e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—MTHFR—atherosclerosis	3.83e-06	3.96e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PPARA—atherosclerosis	3.75e-06	3.89e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PTGS2—atherosclerosis	3.73e-06	3.87e-05	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—AKT1—atherosclerosis	3.65e-06	3.78e-05	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—AKT1—atherosclerosis	3.64e-06	3.77e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—AGT—atherosclerosis	3.63e-06	3.76e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—ALB—atherosclerosis	3.61e-06	3.74e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—APOE—atherosclerosis	3.56e-06	3.69e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—CAV1—atherosclerosis	3.53e-06	3.65e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—APOA1—atherosclerosis	3.52e-06	3.65e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—IL6—atherosclerosis	3.47e-06	3.59e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—NOS3—atherosclerosis	3.46e-06	3.58e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—IL6—atherosclerosis	3.4e-06	3.52e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—IL6—atherosclerosis	3.32e-06	3.44e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PIK3CG—atherosclerosis	3.21e-06	3.33e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—AKT1—atherosclerosis	3.2e-06	3.32e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PTGS2—atherosclerosis	3.16e-06	3.27e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—AKT1—atherosclerosis	3.13e-06	3.24e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PPARG—atherosclerosis	3.1e-06	3.21e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—AKT1—atherosclerosis	3.06e-06	3.17e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—INS—atherosclerosis	3.04e-06	3.15e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—ALB—atherosclerosis	2.79e-06	2.89e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—NOS3—atherosclerosis	2.67e-06	2.76e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—AKT1—atherosclerosis	2.64e-06	2.73e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—AKT1—atherosclerosis	2.49e-06	2.58e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PTGS2—atherosclerosis	2.44e-06	2.53e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—AKT1—atherosclerosis	2.04e-06	2.11e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—AKT1—atherosclerosis	1.99e-06	2.06e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—AKT1—atherosclerosis	1.88e-06	1.94e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—AKT1—atherosclerosis	1.59e-06	1.65e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—AKT1—atherosclerosis	1.23e-06	1.27e-05	CbGpPWpGaD
